These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 38057096)

  • 1. [Erratum: Pharmacological profile and clinical efficacy of imeglimin hydrochloride (TWYMEEG
    Nihon Yakurigaku Zasshi; 2023; 158(4):343. PubMed ID: 38057096
    [No Abstract]   [Full Text] [Related]  

  • 2. [Pharmacological profile and clinical efficacy of imeglimin hydrochloride (TWYMEEG
    Nagamine J
    Nihon Yakurigaku Zasshi; 2023; 158(2):193-202. PubMed ID: 36858505
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Imeglimin Hydrochloride: First Approval.
    Lamb YN
    Drugs; 2021 Sep; 81(14):1683-1690. PubMed ID: 34472031
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imeglimin: A Clinical Pharmacology Review.
    Chevalier C; Fouqueray P; Bolze S
    Clin Pharmacokinet; 2023 Oct; 62(10):1393-1411. PubMed ID: 37713097
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of Imeglimin in Caucasian and Japanese Healthy Subjects.
    Fouqueray P; Chevalier C; Bolze S
    Clin Drug Investig; 2022 Sep; 42(9):721-732. PubMed ID: 35867199
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Imeglimin exerts favorable effects on pancreatic β-cells by improving morphology in mitochondria and increasing the number of insulin granules.
    Sanada J; Obata A; Fushimi Y; Kimura T; Shimoda M; Ikeda T; Nogami Y; Obata Y; Yamasaki Y; Nakanishi S; Mune T; Kaku K; Kaneto H
    Sci Rep; 2022 Aug; 12(1):13220. PubMed ID: 35918386
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of imeglimin in patients with type 2 diabetes mellitus: A systematic review and meta-analysis of randomized clinical trials.
    Abdelhaleem IA; Salamah HM; Alsabbagh FA; Eid AM; Hussien HM; Mohamed NI; Ebada MA
    Diabetes Metab Syndr; 2021; 15(6):102323. PubMed ID: 34717136
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of patient characteristics on the efficacy and safety of imeglimin monotherapy in Japanese patients with type 2 diabetes mellitus: A post-hoc analysis of two randomized, placebo-controlled trials.
    Hagi K; Kochi K; Watada H; Kaku K; Ueki K
    J Diabetes Investig; 2023 Sep; 14(9):1101-1109. PubMed ID: 37264517
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term safety and efficacy of imeglimin as monotherapy or in combination with existing antidiabetic agents in Japanese patients with type 2 diabetes (TIMES 2): A 52-week, open-label, multicentre phase 3 trial.
    Dubourg J; Fouqueray P; Quinslot D; Grouin JM; Kaku K
    Diabetes Obes Metab; 2022 Apr; 24(4):609-619. PubMed ID: 34866306
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanism of action of Imeglimin: A novel therapeutic agent for type 2 diabetes.
    Hallakou-Bozec S; Vial G; Kergoat M; Fouqueray P; Bolze S; Borel AL; Fontaine E; Moller DE
    Diabetes Obes Metab; 2021 Mar; 23(3):664-673. PubMed ID: 33269554
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A review of phenformin, metformin, and imeglimin.
    Yendapally R; Sikazwe D; Kim SS; Ramsinghani S; Fraser-Spears R; Witte AP; La-Viola B
    Drug Dev Res; 2020 Jun; 81(4):390-401. PubMed ID: 31916629
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Imeglimin, a novel glimin oral antidiabetic, exhibits a good efficacy and safety profile in type 2 diabetic patients.
    Pirags V; Lebovitz H; Fouqueray P
    Diabetes Obes Metab; 2012 Sep; 14(9):852-8. PubMed ID: 22519919
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy, safety and tolerability of imeglimin in patients with type 2 diabetes mellitus: A meta-analysis of randomized controlled trials.
    Hagi K; Nitta M; Watada H; Kaku K; Ueki K
    J Diabetes Investig; 2023 Nov; 14(11):1246-1261. PubMed ID: 37610062
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Imeglimin: A New Promising and Effective Weapon in the Treatment of Type 2 Diabetes.
    Doupis J; Baris N; Avramidis K
    touchREV Endocrinol; 2021 Nov; 17(2):88-91. PubMed ID: 35118453
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of imeglimin add-on to insulin monotherapy in Japanese patients with type 2 diabetes (TIMES 3): A randomized, double-blind, placebo-controlled phase 3 trial with a 36-week open-label extension period.
    Reilhac C; Dubourg J; Thang C; Grouin JM; Fouqueray P; Watada H
    Diabetes Obes Metab; 2022 May; 24(5):838-848. PubMed ID: 34984815
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical pharmacology of imeglimin for the treatment of type 2 diabetes.
    Johansson KS; Brønden A; Knop FK; Christensen MB
    Expert Opin Pharmacother; 2020 Jun; 21(8):871-882. PubMed ID: 32108532
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The efficacy and safety of imeglimin as add-on therapy in patients with type 2 diabetes inadequately controlled with sitagliptin monotherapy.
    Fouqueray P; Pirags V; Diamant M; Schernthaner G; Lebovitz HE; Inzucchi SE; Bailey CJ
    Diabetes Care; 2014 Jul; 37(7):1924-30. PubMed ID: 24722500
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imeglimin: a new antidiabetic drug with potential future in the treatment of patients with type 2 diabetes.
    Nowak M; Grzeszczak W
    Endokrynol Pol; 2022; 73(2):361-370. PubMed ID: 35381095
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and Safety of Imeglimin Monotherapy Versus Placebo in Japanese Patients With Type 2 Diabetes (TIMES 1): A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Phase 3 Trial.
    Dubourg J; Fouqueray P; Thang C; Grouin JM; Ueki K
    Diabetes Care; 2021 Apr; 44(4):952-959. PubMed ID: 33574125
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Effects of Imeglimin on the Daily Glycemic Profile Evaluated by Intermittently Scanned Continuous Glucose Monitoring: Retrospective, Single-Center, Observational Study.
    Oda T; Satoh M; Nagasawa K; Sasaki A; Hasegawa Y; Takebe N; Ishigaki Y
    Diabetes Ther; 2022 Sep; 13(9):1635-1643. PubMed ID: 35895275
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.